Last reviewed · How we verify
DCC-2618
DCC-2618 is a tyrosine kinase inhibitor that targets KIT, PDGFRA, and other receptor tyrosine kinases involved in gastrointestinal stromal tumors and other malignancies.
DCC-2618 is a tyrosine kinase inhibitor that targets KIT, PDGFRA, and other receptor tyrosine kinases involved in gastrointestinal stromal tumors and other malignancies. Used for Gastrointestinal stromal tumor (GIST), including imatinib-resistant and sunitinib-resistant disease, Advanced systemic mastocytosis.
At a glance
| Generic name | DCC-2618 |
|---|---|
| Also known as | ripretinib, Ripretinib |
| Sponsor | Deciphera Pharmaceuticals, LLC |
| Drug class | Tyrosine kinase inhibitor |
| Target | KIT, PDGFRA |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
DCC-2618 selectively inhibits multiple tyrosine kinases including KIT and PDGFRA, which are frequently mutated in gastrointestinal stromal tumors (GIST). By blocking these kinases, the drug prevents aberrant signaling that drives tumor cell proliferation and survival. It is designed to overcome resistance mechanisms that develop with earlier-generation KIT inhibitors.
Approved indications
- Gastrointestinal stromal tumor (GIST), including imatinib-resistant and sunitinib-resistant disease
- Advanced systemic mastocytosis
Common side effects
- Diarrhea
- Nausea
- Fatigue
- Vomiting
- Abdominal pain
- Anemia
Key clinical trials
- A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies (PHASE1, PHASE2)
- A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib (PHASE3)
- A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib (PHASE3)
- A Study of DCC-2618 (Ripretinib) In Patients With With Advanced Gastrointestinal Stromal Tumors (GIST) (PHASE2)
- A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib (PHASE2)
- A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies (PHASE1)
- Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies (PHASE3)
- Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DCC-2618 CI brief — competitive landscape report
- DCC-2618 updates RSS · CI watch RSS
- Deciphera Pharmaceuticals, LLC portfolio CI